A genetic variant carried by about 1 in 20 chemotherapy patients can turn a standard drug dose into a dangerous one. University of Michigan researcher Daniel Hertz discusses the research behind expanded genetic testing and why it matters for patients.
We use cookies to ensure you get the best experience on our website. By using this site, you accept our use of cookies.